Advances in Cancer Immunotherapy™:
A Focus on Gynecologic Cancers

This program has already taken place:
Tuesday, Dec. 14, 2021
12-4 p.m. EST
Hosted on Zoom Webinar
Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for gynecologic cancers.

Organizers:

Chrisann Kyi, MD – Memorial Sloan Kettering Cancer Center
Oladapo Yeku, MD, PhD – Massachusetts General Hospital

Program Agenda

12–12:30 p.m.	Brief Introduction to the Types of Immunotherapy Used in Gynecologic Cancers and Current Approvals Mary L. Disis, MD, FACP – University of Washington
12:30–1:15 p.m.	Uterus, Cervix, and Vulva Cancer Updates Roisin O’Cearbhaill, MD – Memorial Sloan Kettering Cancer Center
1:15–2 p.m.	Ovarian Cancer and Biomarkers Updates Emese Zsiros, MD, PhD – Roswell Park Cancer Institute
2–2:15 p.m.	Break
2:15–2:55 p.m.	A Review of Cancer Immunotherapy Toxicity in Practice Kerry L. Reynolds, MD – Massachusetts General Hospital
2:55–3:55 p.m.	Faculty Panel Amy Bregar, MD – Massachusetts General Hospital Mary L. Disis, MD, FACP – University of Washington Roisin O’Cearbhaill, MD – Memorial Sloan Kettering Cancer Center Kerry L. Reynolds, MD – Massachusetts General Hospital Shannon N. Westin – MD Anderson Cancer Center Emese Zsiros, MD, PhD – Roswell Park Cancer Institute
3:55–4 p.m.	Closing Remarks

Program Learning Objectives

Identify the cancer immunotherapy approaches in use for the treatment of gynecologic cancers.
Summarize recent updates in cancer immunotherapy for gynecologic cancers and toxicity management for key disease states.
Implement cancer immunotherapy for gynecologic cancer into clinical practice appropriately.

Case Study Submission Information:
To submit closed/past case studies for live expert panel feedback, please indicate your interest in the checkbox in program registration and SITC staff will follow up with you through email with further instruction.

Target Audience
The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute of Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

Avoid Fraudulent ACI Registration Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org.

If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact SITC Staff prior to the live event at (414) 271-2456 or via email education@sitcancer.org.

The ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Postgraduate Institute for Medicine SITC Logo

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc. (as of 10/13/2021)

The 2021-2022 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Association of Community Cancer Centers, Advances Practitioner Society for Hematology and Oncology, and Hematology/Oncology Pharmacy Association.